Santen and Chongqing Kerui set up new ophthalmic joint venture in China

23 March 2016

Japanese ophthalmology specialist Santen Pharmaceutical (TYO: 4536) and state-owned Chinese group Chongqing Kerui have joined forces in a partnership promised to provide people in China with affordable ophthalmic products.

The Japanese company will take on the name Santen China in the collaboration, which will include the establishment of a manufacturing site in the city of Chongqing, one of four direct-controlled Chinese municipalities. This will be the largest site for making ophthalmic medicines in China.

Both firms have stated that the aim of the joint venture is to provide the highest-quality ophthalmic products at a reasonable price to the most patients possible in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK